Lucid Diagnostics — Third Quarter 2026 Earnings Summary

Lucid Diagnostics reported that Medicare now fully reimburses its EsoGuard esophageal DNA test nationwide, enabling the company to accelerate commercialization efforts. In the third quarter of 2026, the company recognized $1.2 million in revenue from 2,871 tests, with October setting a record volume of over 1,800 tests. The company announced a $15 million private placement to strengthen its balance sheet and reported a GAAP net loss of $6.7 million for the quarter. Additionally, Lucid highlighted the publication of a large-scale real-world study and the inclusion of its test in draft American Gastroenterological Association guidelines as alternatives to endoscopy.